View in EDS HTML Full Text PDF Full Text

Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world

Saved in:
Bibliographic Details
Title: Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
Authors: Kapelios, Chris J.1 (AUTHOR), Lainscak, Mitja2 (AUTHOR), Savarese, Gianluigi3 (AUTHOR), Laroche, Cécile4 (AUTHOR), Seferovic, Petar5 (AUTHOR), Ruschitzka, Frank6 (AUTHOR), Coats, Andrew7 (AUTHOR), Anker, Stefan D.8 (AUTHOR), Crespo‐Leiro, Maria G.9 (AUTHOR), Filippatos, Gerasimos10 (AUTHOR), Piepoli, Massimo F.11 (AUTHOR), Rosano, Giuseppe12 (AUTHOR), Zanolla, Luisa13 (AUTHOR), Aguiar, Carlos14 (AUTHOR), Murin, Jan15 (AUTHOR), Leszek, Przemyslaw16 (AUTHOR), McDonagh, Theresa17 (AUTHOR), Maggioni, Aldo P.4,18 (AUTHOR), Lund, Lars H.3 (AUTHOR) lars.lund@alumni.duke.edu, Auer, J. (AUTHOR)
Source: European Journal of Heart Failure. Nov2019, Vol. 21 Issue 11, p1383-1397. 15p. 4 Charts, 3 Graphs.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13889842
DOI:10.1002/ejhf.1532